Sun Pharma gets 6 USFDA observations for Mohali facility

Written by Ruchika Sharma Published On 2022-08-16T12:30:44+05:30 | Updated On 16 Aug 2022 3:06 PM IST

New Delhi: Drugmaker, Sun Pharmaceutical Industries Limited, has recently announced that the US Food and Drug Administration (USFDA) has concluded an inspection with 6 observations at the company's Mohali manufacturing facility (Punjab, India).

The USFDA conducted an inspection from August 3, 2022 to August 12, 2022.

"At the conclusion of the inspection, the US FDA issued a Form-483, with 6 observations. The Company is preparing the response to the observations, which will be submitted to USFDA within the stipulated timeline," the company stated in its recent BSE filing.

An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

"The Company is committed to address these observations promptly. The Company remains committed to work closely with the USFDA and continues to enhance its compliance on an ongoing basis," the company informed.

Sun Pharma is an Indian multinational pharmaceutical company headquartered in Mumbai, Maharashtra. The company manufacture and market a large basket of pharmaceutical formulations covering a broad spectrum of chronic and acute therapies. It includes generics, branded generics, specialty, complex or difficult to make technology-intensive products, over-the-counter (OTC), antiretrovirals (ARVs), Active Pharmaceutical Ingredients (APIs) and Intermediates.

Read also: LIC reduces stake in Sun Pharma; sells shares worth Rs 3,821 crore in over 1 year

sun pharmasun pharma newsUSFDAUSFDA inspectionmohali facility

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751